NASDAQ : TLSA
Tiziana Life Sciences Ltd — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 0.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.42M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 85.78M |
| Enterprise Value | 83.53M |
Dates
| Measure | Value |
|---|
| Earnings Date | May 1, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 128.03M |
| Shares Outstanding | 128.03M |
| Shares Change (YoY) | +9.05% |
| Shares Change (QoQ) | +6.79% |
| Owned by Insiders (%) | 49.95% |
| Owned by Institutions (%) | 2.09% |
| Float | 64.08M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.69 |
| Quick Ratio | 0.55 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,295.56 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -780.60% |
| Return on Assets (ROA) | -103.16% |
| Return on Invested Capital (ROIC) | -389.08% |
| Return on Capital Employed (ROCE) | 1,213.95% |
| Weighted Average Cost of Capital (WACC) | 6.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.52M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -65.10% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 1.21 |
| Relative Strength Index (RSI) | 26.95 |
| Average Volume (20 Days) | 665,443 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.79M |
| Short Previous Month | 2.64M |
| Short % of Shares Out | 7.67% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.74 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.32M |
| Pretax Income | -25.19M |
| Net Income | -25.19M |
| EBITDA | -23.31M |
| EBIT | -23.32M |
| Earnings Per Share (EPS) | -$0.20 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.18M |
| Total Debt | 932,000 |
| Net Cash | 2.25M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | -2.75M |
| Book Value Per Share | -0.02 |
| Working Capital | -4.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -13.38M |
| Capital Expenditures | -75,000 |
| Depreciation & Amortization | 14,000 |
| Net Borrowing | -278,000 |
| Free Cash Flow | -13.46M |
| FCF Per Share | -$0.11 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.05% |
| Shareholder Yield | -9.05% |
| Earnings Yield | -30.36% |
| FCF Yield | -12.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.11 |
| Price Target Difference | 1,109.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |